Literature DB >> 9801101

Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients.

V Serretta1, D Lo Presti, P Vasile, E Gange, E Esposito, I Menozzi.   

Abstract

OBJECTIVES: To evaluate the nuclear matrix protein 22 (NMP22) test in the management of patients after transurethral resection (TUR) of recurrent transitional cell carcinoma of the bladder.
METHODS: The NMP22 test was performed in 137 patients: in 42 patients, a bladder recurrence was detected by cystoscopy and histologically confirmed; 95 patients were recurrence-free at cytology and cystoscopy performed at least 3 months after TUR.
RESULTS: In patients with tumoral recurrence, the mean NMP22 value was 54.8 U/mL. The false-negative rate was 28.5%. In recurrence-free patients, the mean NMP22 value was 22.8 U/mL. The specificity of the NMP22 test was 61%. Higher NMP22 mean values (29.6 versus 15.8 U/mL) were found in patients who underwent intravesical chemotherapy or immunotherapy.
CONCLUSIONS: Despite its good sensitivity, the NMP22 test cannot be adopted as a routine tool in the surveillance after TUR of patients with superficial bladder cancer because of its low specificity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9801101     DOI: 10.1016/s0090-4295(98)00332-x

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

1.  Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma.

Authors:  D Chao; S J Freedland; A J Pantuck; A Zisman; A S Belldegrun
Journal:  Rev Urol       Date:  2001

2.  Screening and identification of specific markers for bladder transitional cell carcinoma from urine urothelial cells with suppressive subtractive hybridization and cDNA microarray.

Authors:  Baihong Guo; Tuanjie Che; Baoguang Shi; Lijun Guo; Yongsheng Yin; Lin Li; Jinming Wang; Dongwen Yan; Yirong Chen
Journal:  Can Urol Assoc J       Date:  2011-01-13       Impact factor: 1.862

3.  Critical evaluation of urinary markers for bladder cancer detection and monitoring.

Authors:  Shahrokh F Shariat; Jose A Karam; Yair Lotan; Pierre I Karakiewizc
Journal:  Rev Urol       Date:  2008

Review 4.  Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?

Authors:  Samir P Shirodkar; Vinata B Lokeshwar
Journal:  Expert Rev Anticancer Ther       Date:  2008-07       Impact factor: 4.512

Review 5.  Urinary markers in screening patients with hematuria.

Authors:  Edmund Chiong; Kris E Gaston; H Barton Grossman
Journal:  World J Urol       Date:  2007-12-04       Impact factor: 4.226

Review 6.  Defining the role of NMP22 in bladder cancer surveillance.

Authors:  Carvell T Nguyen; J Stephen Jones
Journal:  World J Urol       Date:  2007-12-04       Impact factor: 4.226

7.  Urinary markers for bladder cancer.

Authors:  Zachary L Smith; Thomas J Guzzo
Journal:  F1000Prime Rep       Date:  2013-07-01

Review 8.  An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer.

Authors:  Francesco Soria; Michael J Droller; Yair Lotan; Paolo Gontero; David D'Andrea; Kilian M Gust; Morgan Rouprêt; Marek Babjuk; Joan Palou; Shahrokh F Shariat
Journal:  World J Urol       Date:  2018-06-21       Impact factor: 4.226

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.